Compare Amgen, Inc. (AMGN) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Expeditors International of Wshngtn Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Expeditors International of Wshngtn Inc trades at $172.02 (market cap $22.50B). The key difference: Amgen, Inc. is far larger — about 8.7× Expeditors International of Wshngtn Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | EXPD | |
|---|---|---|
Market Cap | $196.12B | $22.50B |
Sector | Health | Industrials |
52-Week High | $388.16 | $172.02 |
52-Week Low | $271.18 | $111.37 |
Enterprise Value | $241.41B | $21.75B |
Dividend Yield | 2.77% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EXPD trades at $172.02, near its R1 resistance of $173, with a bullish technical outlook supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.71 surpassing the $1.33 expectation. Revenue growth remains steady, reaching $11.07B in 2025, while maintaining strong profitability with a 36.59% ROE. Recent news highlights momentum from e-commerce demand and strategic focus on supply chain management.
The stock presents growth potential driven by earnings momentum and solid fundamentals, but faces headwinds from analyst skepticism (only 12% buy ratings) and valuation concerns with a P/E of 27.79 above industry averages. Key risks include freight market volatility and geopolitical supply chain pressures. The consensus price target of $159 suggests limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
